Plain-English translation of NCT06943495 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new way to deliver radiation treatment for advanced prostate cancer that has stopped responding to hormone therapy. The medication being tested is called Lutetium Lu 177 vipivotide tetraxetan (also known as Pluvicto), a radioactive injection that targets cancer cells. The trial compares two approaches: one where doctors customize the dose based on measurements of how much radiation reaches your kidneys, and one where everyone receives the same standard dose.
Currently, this medication is given at a fixed dose to all patients. Researchers want to know if personalizing the dose—by measuring radiation exposure to the kidneys—could allow doctors to safely give higher amounts of the medication, potentially making it work better for more people.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive up to 6 injections of the medication spaced 6 weeks apart. You will have regular imaging scans (like PET scans), blood tests, and kidney function measurements to monitor how well the treatment is working and how your body is tolerating it. You will also complete questionnaires about any side effects you experience. The entire trial will span several months depending on your treatment schedule.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Canada